Cisplatin nephrotoxicity

Seminars in Nephrology

Volumn 23, Issue 5, 2003, Pages 460-464

  Arany, Istvan ^b   Safirstein, Robert L ^a  

^a Ctrl AR Vet Hlthcare Syst M   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; AMPHOTERICIN; ANTINEOPLASTIC AGENT; CASPASE 3; CISPLATIN; DIETHYLDITHIOCARBAMIC ACID; GENTAMICIN; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN BAD; PROTEIN C JUN; PROTEIN P21; PROTEIN P53; RANTES; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; CELL CYCLE; CELL DEATH; CELL FATE; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; DIURESIS; DNA DAMAGE; DRUG ACCUMULATION; DRUG METABOLISM; DRUG UPTAKE; ENZYME ACTIVATION; GENE REPRESSION; GLOMERULUS FILTRATION RATE; HUMAN; HYPOMAGNESEMIA; INFLAMMATION; KIDNEY DISTAL TUBULE; KIDNEY FAILURE; KIDNEY INJURY; KIDNEY METABOLISM; KIDNEY NECROSIS; KIDNEY PERFUSION; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; METABOLISM; NAUSEA; NEPHRON; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STRESS; VOMITING;

EID: 0141869677     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0270-9295(03)00089-5     Document Type: Article

References (49)

1. Schaeppi U, Heyman IA, Fleischman RW, et al: Cisdichlorodiammine platinum II (NSC 119875): Preclinical toxicologic evaluation of intravenous injections in dogs, monkeys and mice. Toxicol Appl Pharmacol 25:230, 1973
2. Gonzales-Vitale JC, Hayes DM, Cvitrovic E, Sternberg SS: The renal pathology in clinical trials of cis-platinum (II) diamminedichioride. Cancer 39:1362, 1977
3. Litterst CL, Torres IJ, Guarino AM: Plasma levels and organ distribution of platinum in the rat, dog, and dog fish following intravenous administration of cis-DDP(II). J Clin Hemat Oncol 7:169, 1977
4. Safirstein R, et al: Renal disposition and metabolism of liganded platinum: Implications to toxicity. Fed Proc 40:651A, 1980
5. Safirstein R, Miller P, Guttenplan JB: Uptake and metabolism of cisplatin by rat kidney. Kidney Int 25:753, 1984
6. Jacobs C, et al: Renal handling of cis-diammine dichloroplatinum (II). Cancer Treat Rep 64:1223, 1980
7. Safirstein R, et al: Cisplatin nephrotoxicity insights into mechanism. Int J Androl 10:325, 1987
8. Safirstein R, et al: Cisplatin nephrotoxicity in rats: Defect in papillary hypertonicity. Am J Physiol 241:F175, 1982
9. Megyesi J, Safirstein RL, Price PM: Induction of p21WAF1/C3P1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure. J Clin Invest 101:777-782, 1998
10. Safirstein RL, Daye M, Guttenplan JB: Mutagenic activity and identification of excreted platinum in human and rat urine and rat plasma after administration of cisplatin. Cancer Lett 18:329, 1983
11. Rosenberg B: Cisplatin: Its history and possible mechanism of action. Cisplatin - Current Status and New Developments, in Prestayko AW, Crooke ST, Carter SK (eds): New York, Academic, 1980, p 9-20
12. Townsend DM, Hannigan MH: Inhibition of gamma-glutanyl transpeptidase or cysteine S-conjugate beta-lysase activity blocks the nephrotoxicity of cisplatin in mice. J Pharmacol Exper Ther 300:142-148, 2002
13. Fichtinger-Shepman AM, et al: Immunochemical quantitation of adducts induced in DNA by cis-diamminedichloroplatinum (II) and analysis of adduct-related DNA unwinding. Chem Biol Interact 55:275, 1985
14. Harder H, Smith RC, LeRoy A: Template-primer inactivation by cis- and trans-dichlorodiammine platinum for human DNA polymerase a, b, and Rausher murine leukemia virus reverse transcriptase as a mechanism of cytotoxicity. Cancer Res 36:3821, 1976
15. Harder HC, Rosenberg B: Inhibitory effects of antitumor platinum compounds on DNA, RNA, and protein synthesis in mammalian cells in vitro. Cancer 6:207, 1970
16. Levi J, et al: Mechanism of cis-platinum nephrotoxicity: I. Effects on sulfhydryl groups in rat kidneys. Pharmacol Exp Ther 213:545, 1980
17. Safirstein RL: Gene expression in nephrotoxic and ischemic acute renal failure. J Am Soc Nephrol 4:1387-1395, 1994
18. Tibbles LA, Woodgett JR: The stress-activated protein kinase pathways. Cell Mol Life Sci 55:1230-1254, 1999
19. Barr RK, Bogoyevitch MA: The c-Jun N-terminal protein kinase family of mitogen-activated protein kinases (JNK MAPKs). Int J Biochem Cell Biol 33:1047-1063, 2001
20. Weston CR, Davis RJ: The JNK signal transduction pathway. Curr Opin Genet Dev 12:14-21, 2002
21. Zanke BW, Boudreau K, Rubie E, et al: The stress-activated protein kinase pathway mediates cell death following injury induced by cis-platinum, UV irradiation or heat. Curr Biol 6:606-613, 1996
22. Sanchez-Perez I, Perona R: Lack of c-Jun activity increases survival to cisplatin. FEBS Lett 453:151-158, 1999
23. Park MS, De Leon M, Devarajan P: Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways. J Am Soc Nephrol 13:858-865, 2002
24. Kaushal GP, Kaushal V, Hong X, et al: Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells. Kidney Int 60:1726-1736, 2001
25. Cummings BS, Schnellmann RG: Cisplatin-induced renal cell apoptosis: Caspase 3-dependent and -independent pathways. J Pharmacol Exp Ther 302:8-17, 2002
26. Kharbanda S, Saxena S, Yoshida K, et al: Translocation of SAPK/JNK to mitochondria and interaction with Bcl-xL in response to DNA damage. J Biol Chem 275:322-327, 2000
27. Nowak G: Protein kinase C-alpha and ERK1/2 mediate mitochondrial dysfunction, decreases in active Na+ transport, and cisplatin-induced apoptosis in renal cells. J Biol Chem 277:43377-43388, 2002
28. Lieberthal W, Triaca V, Levine J: Mechanism of cell death induced by cisplatin in proximal tubular epithelial cells: Apoptosis vs. necrosis. Am J Physiol 270:F700-F708, 1996
29. Ramesh G, Reeves WB: TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 110:835-842, 2002
30. Kelly KJ, Williams WW Jr, Colvin RB, et al: Antibody to intercellular adhesion molecule-1 protects the kidney against ischemic injury. Proc Natl Acad Sci U S A 91:812-816, 1994
31. Goossens V, Grooten J, De Vos K, et al: Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. Proc Natl Acad Sci U S A 92:8115-8119, 1995
32. Winston JA, Safirstein R: Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. Am J Physiol 249:F490, 1985
33. Daugaard C, Abildgaard U: Cisplatin nephrotoxicity. Cancer Chemother Pharmacol 25:1, 1989
34. Schilsky RL, Anderson T: Hypomagnesaemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 90:929, 1979
35. Vogelzang NJ, Torkelson JL, Kennedy BJ: Hypomagnesaemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer 56:2765, 1985
36. Buckley JE, et al: Hypomagnesemia after cisplatin combination chemotherapy. Arch Intern Med 144:2347, 1984
37. Mavichak V, et al: Studies on the pathogenesis of cisplatin-induced hypomagnesaemia in rats. Kidney Int 28:914, 1985
38. Aass N, et al: Renal function related to different treatment modalities for malignant germ cell tumors. Br J Cancer 62:842, 1990
39. Pera MF, Zook BC, Harder HC: Effects of mannitol or furosemide diuresis on the nephrotoxicity and physiological disposition of cis-dichloroplatinum(II) in rats. Cancer Res 39:1269, 1979
40. Bodenner DL, et al: Effect of diethyldithiocarbamate on cis-diamminedichloroplatinum(II)-induced cytotoxicity, DNA cross-linking and gamma-glutamyl transpeptidase inhibition. Cancer Res 46:2745, 1986
41. Bodenner DL, et al: Selective protection against cisdiamminedichloroplatinum (II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate. Cancer Res 46:2751, 1986
42. Berry JM, et al: Modification of cisplatin toxicity with diethyldithiocarbamate. J Clin Oncol 8:1585, 1990
43. Hartman JT, Knop S, Fels LM, et al: The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin-ifisfamide-based chemotherapy in patients with solid tumors. Anticancer Drugs 11:1-6, 2000
44. Weiss JF: Pharmacologic approaches to protection against radiation-induced lethality and other damage. Environ Health Persp 105:1473-1478, 1997
45. Santini V, Giles FJ: The potential of amifostine: From cytoprotectant to therapeutic agent. Haematologica 84:1035-1042, 1999
46. Persons DL, Yazlovitskaya EM, Cui W, et al: Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: Inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin Cancer Res 5:1007-1014, 1999
47. Hayakawa J, Ohmichi M, Kurachi H, et al: Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res 60:5988-5994, 2000
48. Hayakawa J, Ohmichi M, Kurachi H, et al: Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J Biol Chem 274:31648-31654, 1999
49. Wang X, Martindale JL, Holbrook NJ: Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem 275:39435-39443, 2000